VBI Vaccines, Inc. (VBIV)

Market Cap	182.28M
Revenue (ttm)	660,000
Net Income (ttm)	-101.58M
Shares Out	258.26M
EPS (ttm)	-0.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	394,246
Open	0.700
Previous Close	0.729
Day's Range	0.700 - 0.740
52-Week Range	0.640 - 3.420
Beta	1.84
Analysts	Buy
Price Target	6.12 (+767.1%)
Earnings Date	Nov 7, 2022

About VBIV

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP progr...

• Industry: Biotechnology
• Employees: 149
• Stock Exchange: NASDAQ
• Ticker Symbol: VBIV

Full Company Profile

Financial Performance

In 2021, VBI Vaccines's revenue was $631,000, a decrease of -40.53% compared to the previous year's $1.06 million. Losses were -$69.75 million, 50.9% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for VBIV stock is "Buy." The 12-month stock price forecast is 6.12, which is an increase of 767.10% from the latest price.

Price Target

$6.12

(767.10% upside)

Analyst Consensus: Buy

Stock Forecasts